Fasting has been shown to decrease chemotherapy‐associated adverse events (AEs), in part through insulin‐like growth factor (IGF‐1) reduction, and may induce a protective effect on normal cells during chemotherapy treatment in mice and people. The purpose of this study was to evaluate the effect of fasting on constitutional, bone marrow and gastrointestinal (GI) AEs, and serum glucose, IGF‐1 and insulin levels in dogs receiving vincristine. The study was a prospective, crossover clinical trial in tumour‐bearing dogs. Dogs were randomized to be fasted for 24 to 28 hours prior to and 6 hours following their first or second vincristine treatment, and fed normally for the alternate dose. A significant reduction in nausea, anorexia, lethargy and serum insulin was observed when dogs were fasted; however, no significant differences were found in other GI symptoms, neutrophil count, serum glucose or IGF‐1. Fasting prior to vincristine therapy is a safe and effective treatment modality that helped mitigate constitutional and GI AEs in tumour‐bearing dogs.

中文翻译：

---

禁食可降低犬长春新碱相关不良事件的发生率

禁食已被证明可以减少化疗相关的不良事件 (AE)，部分原因是胰岛素样生长因子 (IGF-1) 的减少，并且可能在小鼠和人的化疗期间对正常细胞产生保护作用。本研究的目的是评估禁食对接受长春新碱的狗的体质、骨髓和胃肠 (GI) AE 以及血清葡萄糖、IGF-1 和胰岛素水平的影响。该研究是一项针对荷瘤犬的前瞻性交叉临床试验。狗被随机分配在第一次或第二次长春新碱治疗之前 24 至 28 小时和之后 6 小时禁食，并正常喂养交替剂量。当狗禁食时，观察到恶心、厌食、嗜睡和血清胰岛素显着减少；然而，在其他 GI 症状、中性粒细胞计数、血清葡萄糖或 IGF-1 方面没有发现显着差异。长春新碱治疗前禁食是一种安全有效的治疗方式，有助于减轻荷瘤犬的体质和胃肠道不良反应。